Crossmark

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective

Crossref DOI link: https://doi.org/10.1007/s00520-022-07339-1

Published Online: 2022-09-08

Published Print: 2022-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Nilsson, Jonas https://orcid.org/0000-0002-2829-5563
Piovesana, Vittoria

Turini, Marco

Lezzi, Claudio

Eriksson, Jennifer

Aapro, Matti
License Information

Text and Data Mining valid from 2022-09-08

Version of Record valid from 2022-09-08
More Information

Article History

Received: 13 December 2021

Accepted: 13 August 2022

First Online: 8 September 2022

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Jonas Nilsson and Jennifer Eriksson are employees of Icon plc. Icon plc. received funding from Helsinn Healthcare SA for study design, execution, analysis and manuscript development. Vittoria Piovesana and Marco Turini are employees of Helsinn Healthcare SA. Helsinn Healthcare commercializes AKYNZEO® (netupitant palonosetron) worldwide. AKYNZEO® (netupitant palonosetron) is the subject of the present economic analysis. Matti Aapro has been a consultant for many companies developing antiemetics, including Helsinn.

Document is current

Any future updates will be listed below